Tibsovo Global Market Report 2025

The tibsovo market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.08 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. Growth in the historical period has been driven by the rising incidence of AML, increased identification of IDH1 mutations among cancer patients, enhanced awareness around targeted treatments, and a surge in oncology-focused research and development.

The tibsovo market size is expected to see strong growth in the next few years. It will grow to $1.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated expansion is due to the rising preference for targeted cancer medications, broader use of IDH1 inhibitors, heightened investment in biopharmaceutical R&D, and favorable regulatory pathways. Key trends anticipated during the forecast period include growth in precision oncology innovations, strategic alliances and partnerships, progress in small-molecule drug innovations, regulatory green lights, and evolution in therapeutic protocols.

The increasing prevalence of acute myeloid leukemia is expected to propel the growth of the Tibsovo market going forward. Acute myeloid leukemia (AML) is an aggressively progressing cancer of the blood and bone marrow that directly impacts blood cell production, immune function, and overall physical health. This rise in prevalence is largely attributed to the global increase in the aging population, as AML primarily affects older adults. With longer life expectancy, more individuals are reaching the age group most vulnerable to developing this type of leukemia. Tibsovo addresses AML by targeting IDH1-mutated cancer cells to inhibit abnormal cell growth, reduce disease progression, improve treatment response, and enhance survival outcomes by restoring normal blood cell production. For example, in February 2023, the Leukemia Foundation, an Australia-based non-profit organization, reported that between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults (aged 25-65) are expected to be diagnosed with blood cancers, primarily including ALL, AML, and non-Hodgkin lymphoma. As a result, the rising prevalence of acute myeloid leukemia is fueling the growth of the Tibsovo market.

Major companies operating in the Tibsovo market are focusing on obtaining regulatory approvals to broaden the drug’s reach and sustain leadership in IDH1-mutated cancers. Regulatory approvals refer to the official permissions granted by health authorities that enable a drug to be legally marketed and used for designated medical conditions after its safety and effectiveness are confirmed. For instance, in October 2023, Servier Laboratoires, a France-based pharmaceutical company, received approval from the European Commission for Tibsovo (ivosidenib tablets), making it the first and only IDH1-targeted therapy authorized in Europe for two difficult-to-treat cancer types. The drug is approved for use in combination with azacitidine for newly diagnosed AML patients with an IDH1 R132 mutation who are ineligible for standard induction chemotherapy, and as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma harboring the same mutation after at least one prior systemic treatment. This approval, which benefits from orphan drug designation, fulfills critical unmet medical needs and offers new hope for improved outcomes and quality of life for these patients.

In December 2023, Servier Group, a France-based pharmaceutical company offering Tibsovo (ivosidenib tablets) as a targeted therapy for patients with IDH1-mutated cancers, acquired exclusive rights to develop, manufacture, and commercialize Tibsovo from CStone Pharmaceuticals for $44 million. This strategic acquisition aims to expand Servier Group’s presence in the rapidly growing China and Singapore markets by securing exclusive rights to Tibsovo. It also strengthens the company’s oncology portfolio with a targeted therapy for IDH1-mutated cancers and accelerates patient access to this innovative treatment in these key regions. CStone Pharmaceuticals is a China-based biopharmaceutical company that specializes in oncology treatments.

Major players in the tibsovo market are Servier Laboratoires, and Agios Pharmaceuticals.

North America was the largest region in the tibsovo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tibsovo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tibsovo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tibsovo is an oral targeted therapy mainly prescribed for adults diagnosed with acute myeloid leukemia (AML) or cholangiocarcinoma that exhibit a specific mutation in the IDH1 gene. By targeting and inhibiting the mutated IDH1 enzyme, Tibsovo lowers the production of an abnormal metabolite that facilitates cancer cell proliferation, thereby aiding in the restoration of normal cell differentiation and decelerating disease advancement.

Tibsovo is available in various forms including tablets, capsules, combination therapies, and injectable options. The tablet form, which contains ivosidenib, is a convenient oral solid dosage designed for once-daily use. The drug can be administered both orally and intravenously and is distributed through hospital pharmacies, retail outlets, and online platforms. It serves several applications such as cancer therapy, AML treatment, chemotherapy, and precision-targeted therapies. These products are utilized by a range of end users including hospitals, specialized clinics, research centers, and homecare environments.

The tibsovo market research report is one of a series of new reports that provides tibsovo market statistics, including tibsovo industry global market size, regional shares, competitors with a tibsovo market share, detailed tibsovo market segments, market trends and opportunities, and any further data you may need to thrive in the tibsovo industry. This tibsovo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tibsovo market consists of sales of products including oral tablets, extended-release tablets, soft gel capsules, intravenous injection, and subcutaneous injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.